NRXS

Neuraxis is a pre-scale neuromodulation device maker whose story rests entirely on two FDA-cleared products (IB-Stim and RED). The fundamentals show a genuine bright spot — FY2025 revenue grew 32.9% to $3.57M with an 84.2% gross margin, and the device economics ($1,195 each, four per IBS patient) are attractive. But the company is nowhere near self-funding: operating margin is -219%, the FY2025 net loss was $7.80M, and operating cash flow was -$6.43M against just $4.97M of cash on hand. That is roughly nine months of runway, and management's own auditors have 'expressed substantial doubt about our ability to continue as a going concern.' That single disclosure dominates the entire analysis.

Valuation makes the risk acute rather than academic. At $7.14 the market cap is $79.9M, or 22.4x trailing sales — a multiple that prices in years of flawless commercial execution from a company that has accumulated a $64.6M deficit since 2011 and has never earned an operating profit. With cash running out, the near-certain next step is another equity raise; shares outstanding already jumped 55% in FY2025, so existing holders should expect further heavy, likely below-market dilution that the current price does not reflect. The MD&A is explicit that reaching profitability depends on milestones not yet achieved: broader insurer reimbursement and FDA clearance for new indications (post-concussion syndrome, cyclic vomiting, fibromyalgia), neither of which is guaranteed or time-bound.